Duocarmycin analog has cytotoxicity for solid tumor cells that can be used for antibody-drug conjugates (ADCs). Duocarmycins and the analogs acts via binding to the minor groove of DNA and alkylating the nucleobase adenine at the N3 position, which leads to DNA damage and cancer cell death.
Structure of
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
5 mg | $939 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Duocarmycin analogs are highly potent DNA minor-groove alkylating agents and promising ADC cytotoxins used as ADC payloads in antibody-drug conjugates. These compounds bind selectively to the minor groove of DNA, causing irreversible DNA alkylation, strand breaks, and apoptosis in rapidly dividing tumor cells. Their extreme cytotoxicity makes them ideal payload candidates for targeted oncology therapeutics.
Within antibody-drug conjugates, Duocarmycin analogs are conjugated to monoclonal antibodies via cleavable linkers that enable selective payload release inside tumor cells. The ADC remains stable in systemic circulation, reducing off-target toxicity, while intracellular enzymatic cleavage liberates the active cytotoxic agent. This mechanism ensures tumor-specific delivery, maximizing antitumor activity while preserving healthy tissues.
Applications of Duocarmycin analogs include their use in experimental ADCs targeting solid tumors and hematologic malignancies, such as breast cancer, lung cancer, ovarian cancer, and lymphomas. Their high potency allows therapeutic efficacy at low drug-to-antibody ratios (DARs), while chemical modifications enhance stability, linker compatibility, and conjugation efficiency. Researchers leverage Duocarmycin analogs to optimize ADC design, improve intracellular release, and achieve superior antitumor outcomes in next-generation antibody-drug conjugates.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00811 | Duocarmycin DM free base | 1116745-06-2 | |
BADC-00337 | Seco-Duocarmycin TM | 1142188-60-0 | |
BADC-00223 | Duocarmycin A | 118292-34-5 | |
BADC-00362 | Duocarmycin B1 | 124325-93-5 | |
BADC-00341 | Seco-Duocarmycin SA | 152785-82-5 | |
BADC-00605 | Duocarmycin TM | 157922-77-5 | |
BADC-00332 | Seco-DuocarmycinCN | 1613286-54-6 | |
BADC-00333 | Seco-DuocarmycinDMG | 1613286-55-7 | |
BADC-00342 | Seco-Duocarmycin MA | 1613286-57-9 | |
BADC-00609 | Duocarmycin MB | 1613286-58-0 |
What is Duocarmycin analog?
Duocarmycin analog refers to chemically modified derivatives of the natural cytotoxic Duocarmycin family. These analogs are designed for use in ADCs, retaining DNA-alkylating activity while offering improved conjugation properties and stability.
11/9/2022
Dear BOC Sciences, how is Duocarmycin analog used in ADCs?
In ADCs, Duocarmycin analogs are linked to targeting antibodies to deliver potent cytotoxic effects specifically to antigen-expressing cells. This targeted delivery enhances efficacy and reduces systemic toxicity.
5/12/2019
Could you provide guidance on which linker types suit Duocarmycin analogs?
Duocarmycin analogs are compatible with cleavable linkers, allowing controlled intracellular release, and non-cleavable linkers, which enhance circulation stability and pharmacokinetic properties of the ADC.
15/9/2021
Could you advise what handling precautions are needed for Duocarmycin analogs?
Due to their high cytotoxic potential, Duocarmycin analogs must be handled with strict laboratory safety measures, including personal protective equipment, proper containment, and adherence to regulatory guidelines during conjugation and experimental procedures.
5/11/2022
Dear BOC Sciences, what benefits do Duocarmycin analog ADCs provide?
Duocarmycin analog ADCs offer selective cell killing with reduced off-target effects, improving the therapeutic index. Their targeted delivery capability is instrumental for preclinical studies and the development of safer, more effective ADC therapies.
22/5/2022
— Dr. Peter Hall, Senior Scientist (USA)
Duocarmycin analog supplied by BOC Sciences had excellent purity and batch stability.
15/9/2021
— Prof. Isabelle Martin, Medicinal Chemistry Professor (France)
The Duocarmycin analog provided by BOC Sciences exceeded our expectations. Its exceptional purity and well-documented characterization data streamlined our cytotoxic payload development.
22/5/2022
— Dr. Thomas Weber, Medicinal Chemist (Germany)
Consistent Duocarmycin analog quality enabled smooth ADC development.
5/11/2022
— Mr. Thomas Meyer, Principal Investigator (Germany)
The Duocarmycin analog was supplied with comprehensive analytical documentation, which simplified our regulatory reporting. The compound’s strong cytotoxic activity was exactly what we needed.
11/9/2022
— Dr. Daniel Lewis, Principal Investigator (USA)
Excellent support and documentation. Duocarmycin analog facilitated our cytotoxicity assays.
— Ms. Julia Andersson, ADC Development Scientist (Sweden)
The Duocarmycin analog arrived with clear COA and MS data, which made our quality review process straightforward. Its cytotoxic strength matched the expected profile in conjugation experiments.
5/12/2019
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.